-
Je něco špatně v tomto záznamu ?
An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology
L. Kandolf, PA. Ascierto, L. Bastholt, I. Gavrilova, J. Haanen, A. Hauschild, D. Herceg, C. Hoeller, A. Jalovcic Suljevic, JI. Kessels, I. Krajsova, M. Kukushkina, A. Lallas, P. Lorigan, J. Mangana, I. Marquez-Rodas, L. Mazilu, P. Mohr, M....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- dostupnost zdravotnických služeb MeSH
- imunoterapie metody MeSH
- inhibitory kontrolních bodů terapeutické užití MeSH
- lidé MeSH
- melanom * farmakoterapie MeSH
- nádory kůže * farmakoterapie MeSH
- průzkumy a dotazníky MeSH
- registrace * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa MeSH
Advances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.A web-based survey using LimeSurvey was distributed to melanoma experts across 27 European countries from February to April 2022 and updated from February to April 2024. The questionnaire covered the percentage of patients receiving recommended treatments, as well as treatment authorization and reimbursement dates for systemic and adjuvant therapies.There has been significant improvement in the registration and reimbursement of BRAFi/MEKi, anti-PD1, and anti-PD1/anti-CTLA4 therapies, increasing from 48 %, 63 %, and 37 % in 2017 to 96 %, 96 %, and 78 % in 2024, respectively. Despite these gains, restrictions persist. Anti-PD1/anti-CTLA4 combination immunotherapy is still not available without restrictions in 48 % of the surveyed countries. The nivolumab/relatlimab combination is licensed only for PDL-1-negative melanoma and reimbursed in seven countries of Europe. Tebentafusp is reimbursed in 15 countries and talimogene laherpervec in 5. In 2024, adjuvant treatments for stage III melanoma are reimbursed in 22 countries for dabrafenib/trametinib and 24 of 27 for anti-PD1 antibodies. Pembrolizumab and nivolumab are reimbursed in 15 and 8 countries, respectively, for stage IIB/IIC disease.While there have been improvements in the reimbursement of metastatic melanoma treatments in Europe, challenges and discrepancies remain. Further efforts at European and global levels are needed to harmonize and enhance access to cancer medicines.
Clinics of Dermatology Faculty of Medicine of Coimbra University Coimbra Portugal
Department of Dermatology and Medical Oncology Universitair Ziekenhuis Brussel Brussels Belgium
Department of Dermatology Aristotle University of Thessaloniki Thessaloniki Greece
Department of Dermatology Elbe Klinikum Buxtehude Buxtehude Germany
Department of Dermatology Medical University of Vienna Vienna Austria
Department of Dermatology University Hospital Schleswig Holstein Campus Kiel Kiel Germany
Department of Dermatology University Hospital Zurich Zurich Switzerland
Department of Medical Oncology University of Brussels Belgium
Department of Oncodermatology National Cancer Center Sofia Bulgaria
Department of Oncology Christie NHS Foundation Trust University of Manchester United Kingdom
Department of Oncology Faculty of Medicine University of Constanta Romania
Department of Oncology General University Hospital Prague Prague Czech Republic
Department of Oncology Hospital General Universitario Gregorio Marañón Madrid Spain
Department of Oncology Odense University Hospital Odense Denmark
Department of Oncology University Clinical Center of Sarajevo Sarajevo Bosnia and Herzegovina
Department of Oncology University Hospital Centre Zagreb Zagreb Croatia
Department of Oncotherapy University of Szeged Szeged Hungary
Faculty of Medicine Military Medical Academy Belgrade Serbia
FSBI N N Blokhin National Medical Research Center of Oncology Moscow Russia
Institute of Oncology Ljubljana Faculty of Medicine University of Ljubljana Ljubljana Slovenia
Maria Sklodowska Curie National Research Institute of Oncology Warsaw Poland
North Estonia Medical Centre Interdisciplinary Cancer Centre Talinn Estonia
Oncodermatology center of the medical chain Dobrobut Kiev Ukraine
Oncology Clinic Clinical Centre of Montenegro Podgorica Montenegro
The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital Amsterdam Netherlands
University Hospital Tübingen Tübingen Germany
University Skin Cancer Center Kiel University Hospital of Schleswig Holstein Kiel Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009940
- 003
- CZ-PrNML
- 005
- 20250429135036.0
- 007
- ta
- 008
- 250415e20241116enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2024.115124 $2 doi
- 035 __
- $a (PubMed)39721295
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kandolf, L $u Faculty of Medicine, Military Medical Academy, Belgrade, Serbia. Electronic address: lidijakandolf@gmail.com
- 245 13
- $a An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology / $c L. Kandolf, PA. Ascierto, L. Bastholt, I. Gavrilova, J. Haanen, A. Hauschild, D. Herceg, C. Hoeller, A. Jalovcic Suljevic, JI. Kessels, I. Krajsova, M. Kukushkina, A. Lallas, P. Lorigan, J. Mangana, I. Marquez-Rodas, L. Mazilu, P. Mohr, M. Bylaite-Bucinskiene, J. Ocvirk, J. Olah, K. Putnik, P. Rutkowski, P. Saiag, I. Samolyenko, JK. Schwarze, I. Stojkovski, N. Cicmil Sarić, R. Vieira, M. Weichenthal, C. Garbe
- 520 9_
- $a Advances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.A web-based survey using LimeSurvey was distributed to melanoma experts across 27 European countries from February to April 2022 and updated from February to April 2024. The questionnaire covered the percentage of patients receiving recommended treatments, as well as treatment authorization and reimbursement dates for systemic and adjuvant therapies.There has been significant improvement in the registration and reimbursement of BRAFi/MEKi, anti-PD1, and anti-PD1/anti-CTLA4 therapies, increasing from 48 %, 63 %, and 37 % in 2017 to 96 %, 96 %, and 78 % in 2024, respectively. Despite these gains, restrictions persist. Anti-PD1/anti-CTLA4 combination immunotherapy is still not available without restrictions in 48 % of the surveyed countries. The nivolumab/relatlimab combination is licensed only for PDL-1-negative melanoma and reimbursed in seven countries of Europe. Tebentafusp is reimbursed in 15 countries and talimogene laherpervec in 5. In 2024, adjuvant treatments for stage III melanoma are reimbursed in 22 countries for dabrafenib/trametinib and 24 of 27 for anti-PD1 antibodies. Pembrolizumab and nivolumab are reimbursed in 15 and 8 countries, respectively, for stage IIB/IIC disease.While there have been improvements in the reimbursement of metastatic melanoma treatments in Europe, challenges and discrepancies remain. Further efforts at European and global levels are needed to harmonize and enhance access to cancer medicines.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a melanom $x farmakoterapie $7 D008545
- 650 12
- $a registrace $7 D012042
- 650 12
- $a nádory kůže $x farmakoterapie $7 D012878
- 650 _2
- $a dostupnost zdravotnických služeb $7 D006297
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ascierto, P A $u Melanoma. Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy
- 700 1_
- $a Bastholt, L $u Department of Oncology, Odense University Hospital, Odense, Denmark
- 700 1_
- $a Gavrilova, I $u Department of Oncodermatology, National Cancer Center, Sofia, Bulgaria
- 700 1_
- $a Haanen, J $u The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
- 700 1_
- $a Hauschild, A $u Department of Dermatology, University Hospital Schleswig-Holstein - Campus Kiel, Kiel, Germany
- 700 1_
- $a Herceg, D $u Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia
- 700 1_
- $a Hoeller, C $u Department of Dermatology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Jalovcic Suljevic, A $u Department of Oncology, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina
- 700 1_
- $a Kessels, J I $u Department of Dermatology and Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium
- 700 1_
- $a Krajsova, I $u Department of Oncology, General University Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Kukushkina, M $u Oncodermatology center of the medical chain "Dobrobut", Kiev, Ukraine
- 700 1_
- $a Lallas, A $u Department of Dermatology, Aristotle University of Thessaloniki, Thessaloniki, Greece
- 700 1_
- $a Lorigan, P $u Department of Oncology, Christie NHS Foundation Trust, University of Manchester, United Kingdom
- 700 1_
- $a Mangana, J $u Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
- 700 1_
- $a Marquez-Rodas, I $u Department of Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 700 1_
- $a Mazilu, L $u Department of Oncology, Faculty of Medicine, University of Constanta, Romania
- 700 1_
- $a Mohr, P $u Department of Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany
- 700 1_
- $a Bylaite-Bucinskiene, M $u Faculty of Medicine, Centre of Dermatovenereology, Clinic of Infectious Diseases and Dermatovenereology, Vilnius University, Vilnius, Lithuania
- 700 1_
- $a Ocvirk, J $u Institute of Oncology Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Olah, J $u Department of Oncotherapy, University of Szeged, Szeged, Hungary
- 700 1_
- $a Putnik, K $u North Estonia Medical Centre Interdisciplinary Cancer Centre, Talinn, Estonia
- 700 1_
- $a Rutkowski, P $u Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Saiag, P $u Department of General and Oncologic Dermatology, Ambroise Paré hospital, APHP, & EA 4340 "Biomarkers in cancerology and haematooncology", UVSQ, Université Paris-Saclay, Boulogne-Billancourt, 92104, France
- 700 1_
- $a Samolyenko, I $u FSBI "N.N. Blokhin National Medical Research Center of Oncology", Moscow, Russia
- 700 1_
- $a Schwarze, J K $u Department of Medical Oncology, University of Brussels, Belgium
- 700 1_
- $a Stojkovski, I $u University Clinic of Radiotherapy and Oncology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Macedonia
- 700 1_
- $a Cicmil Sarić, N $u Oncology Clinic, Clinical Centre of Montenegro, Podgorica, Montenegro
- 700 1_
- $a Vieira, R $u Clinics of Dermatology, Faculty of Medicine of Coimbra University, Coimbra, Portugal
- 700 1_
- $a Weichenthal, M $u University Skin Cancer Center Kiel, University Hospital of Schleswig-Holstein, Kiel, Germany
- 700 1_
- $a Garbe, C $u University Hospital Tübingen, Tübingen, Germany
- 773 0_
- $w MED00009626 $t European journal of cancer $x 1879-0852 $g Roč. 216 (20241116), s. 115124
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39721295 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135031 $b ABA008
- 999 __
- $a ok $b bmc $g 2311363 $s 1247021
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 216 $c - $d 115124 $e 20241116 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20250415
